Obesity and COVID-19: a call for action from people living with obesity

writing group form Obesity UK; Obesity Empowerment Network; UK Association for the Study of Obesity

doi:10.1016/S2213-8587(20)30236-9

Obesity and COVID-19: a call for action from people living with obesity

writing group form Obesity UK, Obesity Empowerment Network, UK Association for the Study of Obesity

The Hull York Medical School

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	652-654
Number of pages	3
Journal	The Lancet Diabetes and Endocrinology
Volume	8
Issue number	8
DOIs	https://doi.org/10.1016/S2213-8587(20)30236-9
Publication status	Published - 9 Aug 2020

Bibliographical note

Funding Information:
SLB reports grants and personal fees from Novo Nordisk. KR is a trustee of the Association for the Study of Obesity. AAT reports grants, personal fees, and travel support from Sanofi, grants, personal fees and educational events grants from Novo Nordisk, travel support from Merck Sharp and Dohme, personal fees and travel support from Boehringer Ingelheim, personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, and Janssen, equipment and travel support from ResMed, equipment from Philips Resporinics, Impeto Medical, and ANSAR Medical Technologies, grants and non-financial support from Napp, and equipment and support staff from Aptiva. All other authors declare no competing interests.

Access to Document

10.1016/S2213-8587(20)30236-9

Cite this

@article{1562c3fb33804e0cbec1319e3567fa5e,

title = "Obesity and COVID-19: a call for action from people living with obesity",

author = "{writing group form Obesity UK} and {Obesity Empowerment Network} and {UK Association for the Study of Obesity} and {Le Brocq}, S. and K. Clare and M. Bryant and K. Roberts and Tahrani, {A. A.}",

note = "Funding Information: SLB reports grants and personal fees from Novo Nordisk. KR is a trustee of the Association for the Study of Obesity. AAT reports grants, personal fees, and travel support from Sanofi, grants, personal fees and educational events grants from Novo Nordisk, travel support from Merck Sharp and Dohme, personal fees and travel support from Boehringer Ingelheim, personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, and Janssen, equipment and travel support from ResMed, equipment from Philips Resporinics, Impeto Medical, and ANSAR Medical Technologies, grants and non-financial support from Napp, and equipment and support staff from Aptiva. All other authors declare no competing interests. ",

year = "2020",

month = aug,

day = "9",

doi = "10.1016/S2213-8587(20)30236-9",

language = "English",

volume = "8",

pages = "652--654",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Obesity and COVID-19

T2 - a call for action from people living with obesity

AU - writing group form Obesity UK

AU - Obesity Empowerment Network

AU - UK Association for the Study of Obesity

AU - Le Brocq, S.

AU - Clare, K.

AU - Bryant, M.

AU - Roberts, K.

AU - Tahrani, A. A.

N1 - Funding Information: SLB reports grants and personal fees from Novo Nordisk. KR is a trustee of the Association for the Study of Obesity. AAT reports grants, personal fees, and travel support from Sanofi, grants, personal fees and educational events grants from Novo Nordisk, travel support from Merck Sharp and Dohme, personal fees and travel support from Boehringer Ingelheim, personal fees from Lilly, AstraZeneca, Bristol-Myers Squibb, and Janssen, equipment and travel support from ResMed, equipment from Philips Resporinics, Impeto Medical, and ANSAR Medical Technologies, grants and non-financial support from Napp, and equipment and support staff from Aptiva. All other authors declare no competing interests.

PY - 2020/8/9

Y1 - 2020/8/9

UR - http://www.scopus.com/inward/record.url?scp=85088264365&partnerID=8YFLogxK

U2 - 10.1016/S2213-8587(20)30236-9

DO - 10.1016/S2213-8587(20)30236-9

M3 - Comment/debate

C2 - 32653052

AN - SCOPUS:85088264365

SN - 2213-8587

VL - 8

SP - 652

EP - 654

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 8

ER -

Obesity and COVID-19: a call for action from people living with obesity

Bibliographical note

Access to Document

Other files and links

Cite this